Get Adobe Flash player

RELATIONSHIP BETWEEN URICEMIA AND HEART FUNCTION INDICATORS IN PERSONS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS

Аuthors: O. M. Chernatska

Pages: 341–345

Abstract

         

As far as we know, the coexistence of arterial hypertension and type 2 diabetes mellitus is associated with increased risk of heart failure. Furthermore, the rise of uric acid levels is a strong, independent and modified factor of cardiovascular morbidity and mortality.

The aim of our clinical trial was the detail analysis of relationship between uricemia and heart function indicators in persons with arterial hypertension and coexistent type 2 diabetes mellitus.

Our study involved 96 patients with arterial hypertension and coexistent type 2 diabetes mellitus (І group), 25 people with arterial hypertension (ІI group), 15 practically healthy persons treated in Sumy City Clinical Hospital № 1 during 2014−2017 years. The methods of our trial were clinical, anthropometric (height definition), biochemical (uric acid levels determination), instrumental (echocardiography), statistical (Microsoft Excel 2016).

Based on the findings uric acid levels increased in proportion to the left ventricular mass index (r = 0.27; р = 0.0075) in patients with arterial hypertension and type 2 diabetes mellitus. The study proved that the uricemia was unreliablу higher in comorbid patients from the І group with third functional class of chronic heart failure compared with the second.

In conclusion, in patients with arterial hypertension and type 2 diabetes mellitus the increase of uric acid levels is associated with the higher left ventricular mass index which may cause largest heart function disorders.

Further study is required to improve treatment of coexistent pathology by prescription medicines with additional ability of uricemia decrease.

Keywords: uricemia, left ventricular mass index, comorbidity, arterial hypertension, type 2 diabetes mellitus.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Tashchuk VK, Mukhamed Vasek Al Salama. Comorbidity, cardiovascular pathology and treatment of hyperuricemia – does allopurinol prevent the disease? Buk. Med. Herald. 2016;20;2(78):209–212.
  2. Matiukha LF. Arterialna hipertenziia ta yii uskladnennia – hipertonichnyi kryz: stratehii likuvannia ta mozhlyvosti zastosuvannia okremykh preparative. Ukrainskyi medychnyi chasopys. 2016;1(111):53.
  3. Kochueva MN. Ways to increase the adherence to antihypertensive therapy. Liky Ukrainy. 2016;7–8(203–204):23–26.
  4. Mishchenko LA. Hiperurykemiia y arterialna hipertenziia – chy isnuie zviazok? Ukrainskyi kardiolohichnyi zhurnal. 2016;3:24–29.
  5. Chaudhary K, Malhotra K, Sowers J [et al.] Uric Acid – key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal. Med. 2013;3(3):208–220.
  6. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels — the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford). 2008 May;47(5):713–7.
  7. Ogino K, Igawa O, Hisatome I. The other antihyperuricemic agents. Nippon Rinsho. 2008 Apr;66(4):754-7.
  8. Unifikovanyi klinichnyi protokol pervynnoi ta vtorynnoi (spetsializovanoi) medychnoi dopomogy «Tsukrovyi diabet 2 typu»: Nakaz Ministerstva okhorony zdorovia vid 21.12.2012 № 1118. – 118 s.
  9. American Diabetes Association. Standards of Medical Care in Diabetes – 2017. Diabetes Care. 2017;40(1):1−142.
  10. Nakaz Ministerstva okhorony zdorovia vid 24.05.2012 № 384. Onovlena ta adaptovana clinichna nastanova, zasnovana na dokazakh.
  11. ESH/ESC 2013 Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J. 2013;34:2159−2219.
  12. Rekomendatsii Asotsiatsii kardiolohiv Ukrainy z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti. Asotsiatsiia kardiolohiv Ukrainy, Ukrainska asotsiatsiia fakhivtsiv iz tsertsevoi nedostatnosti. Kyiv: 2017. − 65 р.
  13. ESH/ESC 2013 Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J [Internet]. 2013;34(28):2159-219. Retrieved from: https://sfcardio.fr/sites/default/files/pdf/ arterial_hypertension.pdf DOI: 10.1093/ eurheartj/eht151.
  14. ASE committee recommendations. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association DOI: 10.1016/j.echo.2005.10.005.
  15. Kolomiiets MV. Optymizatsiia diahnostyky ta likuvannia khvorykh khronichnoiu sertsevoiu nedostatnistiu iz suputnoiu khronichnoiu khvoroboiu nyrok na pidstavi vyvchennia osoblyvostei porushen obminu ksantyniv [dysertatsiia v Interneti]. Kharkiv: Kharkivska medychna akademiia pisliadyplomnoi osvity; 2015. Retrieved from: http://repo.knmu.edu.ua/handle/ 123456789/17485.
  16. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension [Internet]. 2006 Feb;47(2):195-202. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/16380520 DOI: https://doi.org/10.1161/ 01.HYP.0000200033.14574.14.
  17. Mishchenko LA. Zviazok hiperurykemii z urazhenniam orhaniv-mishenei u khvorykh na hipertonichnu khvorobu. Kardyolohyia: ot nauky k praktyke. 2015;2(15):41-51.